Summary of RadNet (RDNT) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $623 million, a 25% increase from $498 million in Q2 2025.

Adjusted EBITDA: $99.7 million, up 22.7% from $81.2 million in the same quarter last year.

Imaging Center Segment:

Advanced imaging procedural volumes increased significantly, with MRI up 21%, CT up 20.9%, and PET/CT up 31%.

Adjusted EBITDA margin for imaging centers improved to 16.1%, a 17 basis point increase year-over-year.

Digital Health Revenue: $32.4 million, a 56.5% year-over-year increase, driven by AI and enterprise imaging solutions.

Annual Recurring Revenue (ARR): $106 million, up 97% year-over-year.

Cash Position: $726 million with a net debt to adjusted EBITDA ratio of 1.8 times.

2Strategic Updates and Business Highlights

Continued strong demand for advanced imaging services, attributed to industry trends and capital investments to expand capacity.

Expansion of joint ventures with health systems, now comprising 36% of imaging centers, including a new partnership in Boise, Idaho.

Digital Health segment showing robust growth with significant contributions from recent acquisitions (Gleamer, C-MODE, iCAD) and a strong pipeline for clinical AI and enterprise informatics.

Successful FDA clearance for DeepHealth breast ultrasound, expected to enhance operational efficiency and revenue potential.

3Forward Guidance and Outlook

Increased full-year guidance for imaging center revenue to $2.37 billion - $2.42 billion and adjusted EBITDA to $345 million - $358 million.

Free cash flow guidance raised to $115 million - $125 million.

Continued investment in technology and digital health solutions expected to drive future growth, with a target of $140 million in ARR by year-end 2026.

4Bad News, Challenges, or Points of Concern

Ongoing labor shortages for technologists and radiologists continue to pressure operational capacity and costs.

The Medicare proposed fee schedule indicates a potential decrease in reimbursement rates, which could impact future revenue, although the overall effect is expected to be minimal.

Integration costs from recent acquisitions have temporarily diluted margins, but these are anticipated to improve as operations stabilize.

5Notable Q&A Insights

Management emphasized the importance of AI in improving radiologist efficiency and addressing staffing shortages, with expectations of significant productivity gains from automated draft reporting.

The company is optimistic about the reimbursement ramp-up for breast ultrasound AI, projecting faster adoption compared to thyroid ultrasound.

Discussions around future acquisitions indicate a balanced approach between digital health and imaging services, with a focus on smaller, strategic deals.

The management acknowledged that while backlogs exist, they are actively managing capacity through new center openings and technology upgrades to mitigate patient wait times. Overall, RadNet reported strong financial performance in Q2 2026, driven by growth in advanced imaging and digital health, while navigating challenges related to labor shortages and potential reimbursement changes. The company remains optimistic about its strategic initiatives and future growth prospects.